Camperdown hemoglobin associated with $\beta^o$ thalassemia in a Brazilian child

Tania Regina Tozetto-Mendoza$^{1,2}$, Paulo Roberto Santos Ferreira$^{1,3}$, Nilcíea Maria Viviani$^4$, Dulcinéia Martins Albuquerque$^5$, Ivana Rizzi$^6$ and João Targino de Araújo$^1$

$^1$Universidade de São Paulo, Instituto de Medicina Tropical de São Paulo, Laboratório de Hematologia Tropical, Serviço de Hematologia, Hospital das Clínicas, São Paulo, SP, Brazil.
$^2$Universidade de São Paulo, Faculdade de Medicina, Laboratório de Investigação Médica, LIM-52, São Paulo, SP, Brazil.
$^3$Universidade de São Paulo, Faculdade de Medicina, Laboratório de Investigação Médica, LIM-31, São Paulo, SP, Brazil.
$^4$Universidade de São Paulo, Hospital das Clínicas, Laboratório de Bioquímica Clínica, São Paulo, SP, Brazil.
$^5$Universidade Estadual de Campinas, Laboratório de Genoma e Hemoglobinopatias, Campinas, SP, Brazil.
$^6$Hospital Candido Fontoura, São Paulo, SP, Brazil.

Abstract

We report the coexistence of Hb Camperdown [c104 (G6) Arg $\rightarrow$ Ser] and $\beta^o$-thalassemia [c39 (Gln $\rightarrow$ stop codon)] in a nine-month-old Brazilian boy. He had a relatively more severe hypochromic and microcytic anemia in comparison to his mother’s $\beta^o$-thalassemia trait. His Hb Camperdown heterozygous father was clinically and hematologically normal. To our knowledge, this is the first description of an association of $\beta^o$-thalassemia with Hb Camperdown.

Key words: hemoglobin Camperdown, thalassemia.

Received: June 24, 2004; Accepted: March 14, 2005.

Inherited hemoglobin disorders are the most common single-gene diseases known, and approximately 1000 different mutant alleles have been identified, occurring widely throughout the tropics (Old, 2003; Weatherall and Clegg, 2001; Zago and Costa, 1985). The well-defined forms of hemoglobin disorders vary considerably within and between ethnic groups, and both ethnicity and environment are important factors in the analysis of genotype/phenotype correlations, as demonstrated by the clinical diversity of $\beta$-thalassemia (Thein, 2004).

Twenty-five years have elapsed since a mutation in the $\beta$-globin gene was first reported as the cause of $\beta$-thalassemia (Chang and Kan, 1979). Currently, almost 200 different mutations have been described which cause beta-globin imbalance, leading to anemia of variable severity (Fonseca et al., 1998; Olivieri, 1999). The association of thalassemia and structural hemoglobin variants produces a wide spectrum of clinical and hematological outcomes, ranging from severe to moderate microcytic hypochromic anemia to no significant clinical alterations (Olivieri, 1999).

Although data on the extent of the diversity of hemoglobin disorders in Brazil are incomplete (Old, 2003; Zago and Costa, 1985; Fonseca et al., 1998; Araújo et al., 2003), many $\beta$-globin mutant alleles have been detected in patients from different Brazilian regions (Araújo et al., 2003; Fonseca et al., 1998; Grignoli et al., 2000).

Herein we describe the co-inheritance of a rare hemoglobin variant and $\beta$-thalassemia in a Brazilian child.

A nine-month-old Brazilian boy was referred to the Department of Diagnosis of Hemoglobin Disorders at the “Hospital das Clínicas” of the São Paulo State University School of Medicine because his mother was a carrier of thalassemia minor. Blood samples of the child were submitted to routine hemoglobin electrophoresis and a subtle change in the electrophoretic pattern was observed on cellulose acetate, demonstrating a fast moving abnormality.
Familial study was then undertaken. The propositus and his father presented abnormal hemoglobin migration, i.e., faster than Hb A, on cellulose acetate, pH 8.9 (Figure 1), and their blood migration patterns on citrate agar, pH 6.1, were slightly different from that of Hb F. After isoelectrofocusing, the abnormal hemoglobin showed a migration pattern slightly more cathodic than Hb A, indicating a decrease in the number of positive charges. Electrophoresis of the globin chain revealed a β-chain variant with a slower migration rate than that of the normal one (Figure 1). High Pressure Liquid Chromatography (HPLC) analysis demonstrated a variant hemoglobin fraction characterized by concentration values of 83.5% and 49.6%, in the propositus and his father, respectively, as well as a retention time of 1.26 minutes. Additionally, the propositus' hematological profile - high RBC (red blood cell), low MCV (mean cell volume), and raised Hb A2 - was strongly suggestive of an interaction with the thalassemia trait (Table 1).

The double mutation of β-globin genes in the propositus was subsequently confirmed by DNA sequencing of exon 2 of the β-globin. DNA samples were isolated from peripheral blood leukocytes. We used the primers described by Kimura et al. (2003). PCR (polymerase chain reaction) was performed with the upstream primer (P1) 5'-TCCTAAGCGTTGCGCAAG-3' and the downstream primer (P5) 5'-TCATTCTCGTCTTGGTCCCATTG-3'. Automatic backward and forward sequencing (ABI DNA sequencer, model 377, Applied Biosystems, Foster City, CA, USA) was performed with the upstream primer (β) 5'-TGTGCTTCTGACACAAGTG-3' and the downstream primer (P5), using an ABI PRISM Big Dye Terminator Cycle sequencing Kit. The propositus and his mother were found to be heterozygous for a nonsense mutation: the C → T substitution at the first nucleotide position of the 39th codon, in exon 2 of the β-globin gene, creates a stop codon resulting in premature termination of the globin chain synthesis. This β-thalassemia mutation is common in the Mediterranean population and is also one of the most frequent β-globin mutations found in Brazil (Fonseca et al., 1998). Another β-globin gene mutation was detected in the propositus and his father: the β104 (G6) arginine residue was replaced by serine [β104(G6) Arg → Ser], resulting in the variant Camperdown Hemoglobin (Hb Camperdown). Therefore, the DNA sequence analysis of the β-globin genes revealed the coexistence of β°-thalassemia and Hb Camperdown mutations in the propositus.

This is the first report of the co-occurrence of Hb Camperdown and β°-thalassemia. β-thalassemia heterozygotes manifest a typical clinical picture, characterized by mild anemia, reduction in mean cell volumes and in mean cell hemoglobin concentrations, elevated concentrations of HbA2, altered erythrocyte morphology, and imbalance of globin-chain synthesis with an alpha/beta ratio > 1 (Bianco et al., 1977). Hb Camperdown is considered slightly unstable, resulting in a benign clinical course in heterozygous individuals (Wilkinson et al., 1975; Blouquit et al., 1984; Kister et al., 1989; Miranda et al., 1996). This hemoglobin mutation leads to a slightly decreased molecular stability, due to the positively charged residues lining the β1β2 interface, where anionic cofactors bind to tetrameric hemoglobin (Arnone, 1972). It was first described by Wilkinson et al. (1975) in a woman of Maltese origin, and several other carriers of this mutant hemoglobin were later described originating from countries bordering the Mediterranean Sea (Blouquit et al., 1984). Miranda et al. (1996) reported the first case of Hb Camperdown in South America, in a Brazilian woman of Italian descent. Hb Camperdown carriers do not show significant clinical alterations.

The doubly heterozygous child described herein presented a relatively more pronounced hypochromic and microcytic anemia in comparison with his mother’s β-thalassemia trait, while his Hb Camperdown heterozygous father was clinically and hematologically normal. The propositus also presented lower values of MCV and MCH than those obtained by Bertuzzo et al. (1997) in 45 β-thalassemia carriers with the β° 39 mutation, ranging in age from 16 to 66 years. The child’s follow-up will provide information for a better understanding of the clinical impact of the interaction of heterozygosis for both β-thalassemia and Hb Camperdown.
Acknowledgments

We wish to thank Professor Dr. Heitor Franco de Andrade Junior, Professor Dr. Fernando Ferreira Costa, Dr. André Fattore, Dr. Nairo M. Sumita and his coworkers Lia M. de Oliveira and Clovis S. Goussain, for their kind technical advice. This work was partly supported by Laboratório de Investigação Médica da Faculdade de Medicina - LIM 49 - USP/Fundação do Desenvolvimento Administrativo - FUNDAP.

References


Table 1 - Molecular, biochemical and hematological data.

<table>
<thead>
<tr>
<th>DNA sequence variation</th>
<th>Propositus [g. 115 C &gt; T]; [g. 312 G &gt; T]</th>
<th>Mother [g. 115 C &gt; T]</th>
<th>Father [g. 312 G &gt; T]</th>
<th>Brother</th>
<th>No mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>9 m</td>
<td>22 y</td>
<td>24 y</td>
<td>nd²</td>
<td></td>
</tr>
<tr>
<td>Ht g/dL</td>
<td>38.1</td>
<td>37.0</td>
<td>45.4</td>
<td>38.1</td>
<td></td>
</tr>
<tr>
<td>RBC 1012/L</td>
<td>6.81</td>
<td>5.90</td>
<td>5.63</td>
<td>4.94</td>
<td></td>
</tr>
<tr>
<td>MCV g/dL</td>
<td>11.3</td>
<td>11.5</td>
<td>16.1</td>
<td>13.7</td>
<td></td>
</tr>
<tr>
<td>MCH g/dL</td>
<td>16.6</td>
<td>19.5</td>
<td>28.5</td>
<td>27.7</td>
<td></td>
</tr>
<tr>
<td>HbA2³</td>
<td>%</td>
<td>5.2</td>
<td>4.4</td>
<td>2.6</td>
<td>2.4</td>
</tr>
<tr>
<td>Hb x: Hb Camperdown¹</td>
<td>%</td>
<td>83.5</td>
<td>absent</td>
<td>49.6</td>
<td>Absent</td>
</tr>
<tr>
<td>Hb F¹</td>
<td>%</td>
<td>4.4</td>
<td>1.3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Reticulocytes</td>
<td>%</td>
<td>1.3</td>
<td>2.2</td>
<td>1.3</td>
<td>1.9</td>
</tr>
</tbody>
</table>

¹Analysis by ABI DNA sequencer, model 377, Applied Biosystems, Foster City, CA, USA. Nomenclature based on Human Database Mutation.
²n.d. - not determined data
³Quantification by HPLC, \( \beta \)-thalassemia Short Program (Bio-Rad Laboratories, Hercules, CA, USA).